Field Trip Health & Wellness Ltd.
(TSXV: FTHW) (the “Company” or “Field Trip”), a global leader in the delivery of psychedelic therapies, today announced that it has strengthened its management team with the hiring of two executives superiors.
The Company has appointed Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as vice-president, Integrative health.
, Chairman and CEO, said, “We have deepened the expertise of Field Trip’s leadership team with these talented individuals as we enter this pivotal phase of our growth plans. They bring unique perspectives and extensive track records of working in innovative fields, which will be invaluable as we grow Field Trip, growing our digital communities, and expanding access to assisted legal psychedelic treatments. The addition of the diverse skills of Stacey and Monique will effectively complement our leadership team and support the execution of our broader holistic approach to mental health and wellbeing, which integrates medicine, technology and community to help people to free oneself from depression and anxiety. ‘
is an accomplished corporate and securities lawyer and business leader, with over 20 years of experience and extensive experience in corporate governance, commercial law, regulatory compliance, public and private mergers and acquisitions, FinTech and capital markets. More recently, Ms Hoisak
has served as Chief Executive Officer, Chief Legal Officer, Chief Privacy Officer and Director of Coinsquare Ltd.
Previously, she served as General Counsel and Corporate Secretary at Birch Hill Equity Partners
and Alpha Exchange, and served as Director of Regulatory Compliance for TMX Group
and a partner in Stikeman Elliott LLP
group of companies/securities. Ms Hoisak
studied at the same time University of New Brunswick
(Pre-Med) and LL.B) and Osgoode Hall Law School
(Masters in Securities Law).
dr. Monique Moller is an esteemed physician with expertise in mental health and addiction, and is passionate about education, research, and clinical initiatives in the psychedelic field. Dr Moller previously held the position of Staff Physician at the Center for Addiction and Mental Health (CAMH) and the addiction service of Women’s College Hospitaland numerous academic roles, including Associate Director of the Addiction Medicine Enhanced Skills Program, Coordinator of Medical Elective Courses for Addictions at CAMH, and Addictions Lead for the Undergraduate Medical Education Core Curriculum. cycle at University of Toronto. Dr Moller created the Addiction Counseling Service at CAMH, developing a strong clinical teaching unit. Dr Moller holds a professorship at the University of Toronto as assistant professor at Mental Health and Addictions Division, Department of Family and Community Medicine as well as pharmacology and toxicology, and also supports True North Medical, the largest virtual addiction medicine program in the province of ontario canada.
Field Trip would also like to thank Paula Amy Hewitt, who resigned as Senior Vice President, General Counsel, Chief Privacy Officer and Corporate Secretary for her many contributions, hard work and dedication to the company and her predecessors. Paula’s innovative advice, strong leadership, and belief in the potential of psychedelics to improve the human condition have been essential to Field Trip’s growth to date. The Society wishes Paula every success in her future endeavours.
Additionally, the Company today announced that it plans to release financial results for its second quarter of fiscal 2023 for the three-month period ended September 30, 2022after market close Monday, November 28, 2022.
The Company will host a conference call and webcast to discuss its results the following morning, Tuesday, November 29, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (in the WE) or 1-201-493-6779 (outside the WE) and provide conference ID 13734182. A live webcast of the conference call can be accessed through the Events & Presentations section of the Field Trip Health and Wellness Investor Relations website here.
For those unable to attend the live call, a telephone replay will be available until 11:59 p.m. ET on Tuesday, December 13, 2022. To access the replay, dial 1-844-512-2921 (in the WE) or 1-412-317-6671 (outside the WE) and provide conference ID 13734182. The webcast will be archived and available in the Events & Presentations section of the Field Trip Health and Wellness Investor Relations website approximately one hour after the conclusion of the live call.
About Field Trip Health & Wellness Ltd.
With a large global community of people interested in psychedelics, proprietary psychedelic therapies generating transformative results for people in treating mental health issues, and a brand and voice that reaches millions, Field Trip is a center for gravity for the Renaissance psychedelic.
Caution Regarding Forward-Looking Information
This press release contains forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) concerning the Company and its business. Often, but not always, forward-looking information can be identified by the use of words such as “expects”, “intends”, “anticipates”, “believes” or variations (including variations negative) of these words and expressions, or declare that certain actions, events or results “may”, “might”, “would” or “will” be taken, will occur or will be achieved. These statements are based on the Company’s management’s current expectations and outlook of future events and are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and may differ materially due to known and unknown risk factors and uncertainties affecting the businesses, including Field Trip’s ability to achieve its business plan, to develop its clientele or its application. user base, adoption of existing or new programs by clinicians or patients, if any, results or ability to commercialize its research and cultivation activities or adoption of any product so developed, acceptance of psychedelic treatments by clinicians, of patients and regulators, the ability or effect of any clinical restructuring, the ability of Field Trip to achieve its business plan for a broader and holistic approach to mental health and well-being and/or future plan changes regulations that govern the activities of Field Trip. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors that cause the actions, events or results differ from those anticipated, estimated or expected, including risk factors contained in the Company’s public filings at www.sedar.com. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether whether as a result of new information, future events or otherwise. Additional information regarding the Company may be found on the SEDAR website at www.sedar.com.
Tel: (416) 505-0929
Email: [email protected]